Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
基本信息
- 批准号:10822885
- 负责人:
- 金额:$ 42.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AmplifiersAnti-Inflammatory AgentsAntigensBacteriaBile Acid Biosynthesis PathwayBile AcidsBile fluidBindingBiochemicalButyratesCD4 Positive T LymphocytesCell physiologyCellsCirculationClassificationColonDataDevelopmentDrug Metabolic DetoxicationDuodenumEffector CellEnteralEnterocytesEnterohepatic CirculationEnzymesEstrogensFOXP3 geneFoundationsGallbladderGene ExpressionGene Expression RegulationGenetic ScreeningGenetic TranscriptionGenomeGenomicsGlucocorticoid ReceptorHealthHepatocyteHistone Deacetylase InhibitorHomeostasisHumanIL10 geneImmuneImmune ToleranceImmunologicsImmunologyInfiltrationInflammationInflammatoryInflammatory Bowel DiseasesInterleukin-10IntestinesLarge IntestineLigand Binding DomainLigandsLinkLiverLocationLymphocyteLymphocyte SubsetMapsMetabolicMetabolismMicrobeMolecularMucosal ImmunityMucositisMucous MembraneMusNuclearNuclear Hormone ReceptorsNuclear ReceptorsOrganOrphanPeripheralProductionRNA InterferenceRNA interference screenReceptor ActivationRegulationRegulatory T-LymphocyteReportingResidual stateRoleSecondary toShapesSmall IntestinesT cell infiltrationT cell responseT-LymphocyteTestingThyroid HormonesToxic effectUlcerative ColitisValidationVitamin D3 ReceptorVolatile Fatty AcidsWild Type MouseXenobioticsabsorptionantagonistconstitutive androstane receptorcytokinedesignfunctional genomicshost-microbe interactionsileumimmunoregulationin vivolipophilicitymembermicrobialmicrobiotanovelnovel strategiesprogramsreceptorresponsescreeningsensorsmall bowel Crohn&aposs diseasesteroid hormonetargeted treatmenttranscription factor
项目摘要
Project Summary
The gut is a major immunological organ where host-microbe interactions shape both local and systemic immune
tolerance. However, current views of intestinal immune regulation ignore fundamental differences in the function
and metabolite composition of the two distinct organs that comprise the gut—the small and large intestine (or SI
and LI). This impedes a more detailed understanding of immune regulatory mechanisms along the intestinal
tract, and limits efforts to develop safer, more targeted treatments for the two major forms of human inflammatory
bowel diseases (IBDs), ulcerative colitis and small bowel Crohn’s disease. We hypothesize that mucosal CD4 T
cells use different sets of ligand-regulated nuclear receptors (NRs) in the SI and LI to control key regulatory
functions, including IL-10 expression, to local concentration gradients of bile- and microbe-derived metabolites.
On one hand, we have discovered that Foxp3– effector (Teff) subsets in the SI—including Th1 and Th17 cells—
utilize the nuclear xenobiotic receptor, constitutive androstane receptor (CAR/Nr1i3), to direct a ‘hepatocyte-like’
transcriptional response to contend with high local bile acid (BA) concentrations, which are far greater in SI than
in LI (millimolar vs micromolar) due to ‘enterohepatic’ circulation—where primary BAs synthesized in the liver,
stored in the gallbladder, and secreted into the duodenum are actively reabsorbed by specialized enterocytes in
the ileum for portal recirculation to the liver. Because BAs are lipophilic, they can be toxic and pro-inflammatory,
and several nuclear receptors—including CAR—have evolved to suppress BA toxicity. These studies suggest
that enterohepatic circulation establishes a unique SI microenvironment that is distinct from that in the LI and
requires unique transcriptional machinery to protect T cells in the SI. Conversely, the LI harbors 103-107 times
more bacteria than SI, and ~1000-fold lower BA concentrations. Accordingly, microbes and their metabolites—
short chain fatty acids (SCFAs; e.g., butyrate), secondary BAs (produced via microbial metabolism of residual
primary BAs)—are central to immune regulation in the LI. SCFAs inhibit histone deacetylase enzymes (HDACs)
and stabilize Foxp3 gene expression in peripherally-induced T regulatory cells (iTregs), whereas secondary BAs
appear to promote regulatory functions of RORgt+ Tregs in the LI through another NR, vitamin D receptor (VDR).
Thus, while antigens from the enteric flora prime both pro- and anti-inflammatory T cell responses throughout
the gut, marked concentration gradients of bile- and bacteria-derived metabolites in the SI vs. LI are sensed by
different NRs to execute compartmentalized T cell regulatory functions. In testing this hypothesis, we will apply
cutting-edge genomics and computational approaches to comprehensively map the contributions of each of the
49 mouse NRs to specialized regulatory functions in the SI and LI in vivo, using IL-10 expression as the primary
screening target. We will also interrogate the regulation and molecular functions of two key NRs, CAR/Nr1i3 and
VDR/Nr1i1, in SI type 1 regulatory (Tr1) and LI iTreg cells, respectively. These studies will advance
understanding of lymphocyte specialization in the gut, and inform new approaches to treat IBDs.
项目概要
肠道是一个主要的免疫器官,宿主与微生物的相互作用塑造局部和全身免疫
然而,目前肠道免疫调节的观点忽视了功能的根本差异。
以及构成肠道的两个不同器官——小肠和大肠(或 SI
和 LI)这阻碍了对肠道免疫调节机制的更详细的了解。
道,并限制了为人类两种主要炎症形式开发更安全、更有针对性的治疗方法的努力
肠道疾病 (IBD)、溃疡性结肠炎和小肠克罗恩病 我们勇敢地面对粘膜 CD4 T。
细胞使用 SI 和 LI 中不同组的配体调节核受体 (NR) 来控制关键调节
功能,包括 IL-10 表达,与胆汁和微生物衍生代谢物的局部浓度梯度相关。
一方面,我们发现 SI 中的 Foxp3 效应子 (Teff) 亚群(包括 Th1 和 Th17 细胞)
利用核异生素受体、组成型雄甾烷受体 (CAR/Nr1i3) 来指导“肝细胞样”
应对高局部胆汁酸 (BA) 浓度的转录反应,SI 中的胆汁酸浓度远高于
由于“肠肝”循环,初级 BA 在肝脏中合成,导致 LI(毫摩尔与微摩尔)
储存在胆囊中并分泌到十二指肠中,并被专门的肠细胞主动重吸收
由于 BA 是亲脂性的,因此它们可能具有毒性和促炎性,
这些研究表明,包括 CAR 在内的几种核受体已经进化出抑制 BA 毒性的能力。
肠肝循环建立了一个独特的 SI 微环境,与 LI 中的微环境不同,
需要独特的转录机制来保护 SI 中的 T 细胞离线,LI 包含 103-107 倍。
比 SI 更多的细菌,并且 BA 浓度低约 1000 倍,因此,微生物及其代谢物——
短链脂肪酸(SCFA;例如丁酸)、次生 BA(通过残余物的微生物代谢产生)
初级 BA)——SCFA 抑制组蛋白脱乙酰酶 (HDAC) 的免疫调节核心。
和 Foxp3 基因在外周诱导的 T 调节细胞 (iTreg) 中表达,而次级 BA
似乎通过另一种 NR、维生素 D 受体 (VDR) 促进 LI 中 RORgt+ Tregs 的调节功能。
因此,虽然来自肠道菌群的抗原在整个过程中引发促炎和抗炎 T 细胞反应
在肠道中,SI 与 LI 中胆汁和细菌衍生代谢物的显着浓度梯度由
在检验这一假设时,我们将应用不同的 NR 来执行区室化的 T 细胞调节功能。
尖端的基因组学和计算方法来全面绘制每个基因组的贡献
49 小鼠体内 SI 和 LI 中专门调节功能的 NR,使用 IL-10 表达作为主要
我们还将探讨两个关键 NR CAR/Nr1i3 和 CAR/Nr1i3 的调控和分子功能。
VDR/Nr1i1,分别在 SI 1 型调节 (Tr1) 和 LI iTreg 细胞中 这些研究将取得进展。
了解肠道淋巴细胞的专门化,并为治疗 IBD 提供新方法。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quantifying forms and functions of intestinal bile acid pools in mice.
量化小鼠肠道胆汁酸库的形式和功能。
- DOI:
- 发表时间:2024-02-18
- 期刊:
- 影响因子:0
- 作者:Sudo, Koichi;Delmas;Soucy, Shannon;Barrack, Kaitlyn E;Liu, Jiabao;Balasubramanian, Akshaya;Shu, Chengyi Jenny;James, Michael;Hegner, Courtney L;Dionne, Henry D;Rodriguez;Krause, Henry;O'Toole, George A;Karpe
- 通讯作者:Karpe
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Eugene Pipkin其他文献
Matthew Eugene Pipkin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Eugene Pipkin', 18)}}的其他基金
Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
- 批准号:
10283045 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
- 批准号:
10591752 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
- 批准号:
10459564 - 财政年份:2021
- 资助金额:
$ 42.56万 - 项目类别:
shRNAmir and CRISPR sgRNA Library Construction Core
shRNAmir 和 CRISPR sgRNA 文库构建核心
- 批准号:
10683260 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
Chromatin and transcriptional regulatory factors that initiate and stabilize memory CD8 T cell development
启动和稳定记忆 CD8 T 细胞发育的染色质和转录调节因子
- 批准号:
10224893 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
shRNAmir and CRISPR sgRNA Library Construction Core
shRNAmir 和 CRISPR sgRNA 文库构建核心
- 批准号:
10024585 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
Gene expression, Epigenetics and Bioinformatics Core
基因表达、表观遗传学和生物信息学核心
- 批准号:
10591868 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and function
CD4 和 CD8 T 细胞效应及记忆分化和功能的转录因子调节
- 批准号:
10683256 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
Gene expression, Epigenetics and Bioinformatics Core
基因表达、表观遗传学和生物信息学核心
- 批准号:
10024586 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
Chromatin and transcriptional regulatory factors that initiate and stabilize memory CD8 T cell development
启动和稳定记忆 CD8 T 细胞发育的染色质和转录调节因子
- 批准号:
10024588 - 财政年份:2020
- 资助金额:
$ 42.56万 - 项目类别:
相似国自然基金
卡萨烷选择性调控糖皮质激素受体GR功能的抗炎作用机制与新颖调控剂的设计与发现
- 批准号:82273824
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
靶向HDAC3/SIAH2蛋白复合物的HDAC3降解剂的作用机制、结构改造及非酶活功能介导的抗炎活性研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ZAP-70选择性共价抑制剂及降解剂的设计合成和抗炎活性研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于片段的P2Y14受体拮抗剂的设计、合成和抗炎活性研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
两种民族药用植物中黄酮类ILCreg诱导剂的发现及其抗炎性肠病机制探究
- 批准号:81960777
- 批准年份:2019
- 资助金额:34 万元
- 项目类别:地区科学基金项目
相似海外基金
Immunoepigenetic targeting of MHC regulators in FAP
FAP 中 MHC 调节因子的免疫表观遗传学靶向
- 批准号:
10677375 - 财政年份:2023
- 资助金额:
$ 42.56万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 42.56万 - 项目类别:
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry
通过点击化学抗体引导生物正交原药的局部激活
- 批准号:
10760737 - 财政年份:2023
- 资助金额:
$ 42.56万 - 项目类别:
Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase
使用 Cav3 通道和可溶性环氧化物水解酶的 IND 双重抑制剂开发可卡因使用障碍的新型治疗方法
- 批准号:
10786151 - 财政年份:2023
- 资助金额:
$ 42.56万 - 项目类别:
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 42.56万 - 项目类别: